Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085632 (
apathy
)
4,089
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It has been recently demonstrated that the 43-kDa transactive response (TAR)-DNA-binding protein (
TARDBP
) is the neuropathological hallmark of Frontotemporal Dementia (FTD) with ubiquitin-positive and tau-negative inclusions. Large series of FTD patients without motor neuron disease have been previously analysed, but no
TARDBP
mutation was identified. The aim of the present study was to evaluate whether
TARDBP
gene mutations may be associated with FTD. We report that a pathogenetic
TARDBP
mutation is causative of behavioural variant FTD (bvFTD). An aged woman in her seventies initially started to present
apathy
and depression associated with impairment in executive functions. The diagnosis of bvFTD (apathetic syndrome) was accomplished by three-year follow-up, and structural and functional neuroimaging. By five-years after onset, extensive electrophysiological investigations excluded subclinical motor neuron disease. In this patient, a single base substitution c.800A>G of
TARDBP
gene was identified. This mutation, already described as causative of ALS, predicted the amino acidic change arginine to serine at position 267 (N267S). In silico analysis demonstrated that this substitution generates a new phosphorylation site, and western blot analysis on lymphoblastoid cells reported a decrease of protein expression in N267S mutation carrier. Our study suggests that
TARDBP
mutations can be pathogenetic of bvFTD without motor neuron disease.
TARDBP
screening needs to be considered in FTD cases.
...
PMID:Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. 1965 82